The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data
From Beyond Biotech - the podcast from Labiotech · · 38 min
This plays from the publisher's own server. We do not host a copy.
Description
Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio (https://www.ochre-bio.com), a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen (https://www.lexogen.com), an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence.
00:55: The challenges of liver disease
04:44: How Lexogen supports NGS drug discovery
07:29: Major transcriptomics developments
10:05: Designing high quality AI data
15:47: How the Ochre-Lexogen partnership began
17:17: Why a specialist partner is essential for scale
18:21: Lexogen delivers on the massive sequencing project
21:50: Why high quality data is crucial
27:02: Lexogen's role in AI discovery
34:51: Future plans and directions
This episode was produced with the support of Lexogen (https://www.lexogen.com). Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast)
Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast)
To dive deeper into the topic:
- Deep phenotyping brings accuracy to precision medicine (https://www.labiotech.eu/in-depth/precision-medicine-deep-phenotyping/)
- Spatial Transcriptomics: A window into disease (https://www.labiotech.eu/in-depth/spatial-transcriptomics/)
- Spatial Transcriptomics Landscape Shifts With Two Major Acquisitions (https://www.labiotech.eu/trends-news/spatial-transcriptomics-readcoor-10x/)
Back to Beyond Biotech - the podcast from Labiotech · Report a problem